BCMA-Targeted CAR-Ts and Their Role in Late-Relapse Multiple Myeloma
2 Views
administrator
07/14/23
A roundtable discussion, moderated by Saad Usmani, MD, of Memorial Sloan Kettering Cancer Center, focused on treatment considerations for relapsed or refractory multiple myeloma, including updated data from ASCO 2023. Dr. Usmani was joined by a panel that included Yi Lin, MD; Shambavi Richard, MD; and Meera Mohan, MD.
In the next segment of the roundtable series, the panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma, including data from KarMMa-3 and CARTITUDE-4.
-
Category
Show more
Facebook Comments
No comments found